Reply - 10/08/11
Doi : 10.1016/j.jaci.2010.10.052
Michael R. Simon, MD a, Vernon M. Chinchilli, PhD b 
, Brenda R. Phillips, MS b, Christine A. Sorkness, PharmD c, Robert F. Lemanske, MD c, Stanley J. Szefler, MD d, Lynn Taussig, MD e, Leonard B. Bacharier, MD f, Wayne Morgan, MD g
, Brenda R. Phillips, MS b, Christine A. Sorkness, PharmD c, Robert F. Lemanske, MD c, Stanley J. Szefler, MD d, Lynn Taussig, MD e, Leonard B. Bacharier, MD f, Wayne Morgan, MD g a The Division of Allergy and Clinical Immunology, William Beaumont Hospital, Royal Oak, and the Departments of Internal Medicine and Pediatrics, Wayne State University School of Medicine, Detroit, Mich
b Department of Public Health Sciences, Penn State Hershey College of Medicine, Hershey, Pa
c Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis
d Department of Pediatrics, National Jewish Health, Denver, Colo
e Division of Natural Sciences and Mathematics, University of Denver, Denver, Colo
f Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
g Respiratory Sciences Center, University of Arizona College of Medicine, Tucson, Ariz
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: V. M. Chinchilli receives research support from the National Institutes of Health. L. B. Bacharier receives honoraria from AstraZeneca and serves on advisory boards for Genentech, GlaxoSmithKline, Merck, Schering-Plough, and Aerocrine. W. Morgan has consultant arrangements with Genentech, Novartis, and the Cystic Fibrosis Foundation; is a speaker for Phadia AB; and receives research support from the NIH-NHLBI CARE Network and the Cystic Fibrosis Foundation. S. J. Szefler has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and receives research support from the NIH/NHLBI Childhood Asthma Management Program, the NIH/NHLBI Childhood Asthma Research and Education, the NIH/NHLBI Asthma Clinical Research Network, the NIH/NIAID Inner City Asthma Consortium, GlaxoSmithKline, the NJH/NHLBI Asthma Net, and the NEEHS/EPA Childhood Environmental Health Center grant. C. A. Sorkness is on advisory boards for GlaxoSmithKline, Schering Plough, and AstraZeneca and receives research support from Schering Plough and Compleware/Sandoz. R. F. Lemanske is a speaker for Merck, AstraZeneca, Doembacher Children’s Hospital, Washington University, Medicus Group, Parke Nicolet Institute, ACAAI, LA Allergy Society, Michigan Allergy/Asthma Society, Medical College of Wisconsin, Fund for Medical Research and Education (Detroit), Children’s Hospital of Minnesota, Toronto Allergy Society, AAAAI, Beaumont Hospital (Detroit), University of Illinois, Canadian Society of Allergy and Clinical Immunology, New York Presbyterian, Med Media Education Group, Onpointe Medical Communication, Medical University of South Carolina, Health Matters Communication, Bishop McCann, Donohue, Purohit, Miller, Inc, Center for Health Care Education, University of California-San Francisco, American Thoracic Society, University of Iowa, Indiana University, American Lung Association of Upper Midwest, Vanderbilt University, and Rochester Children’s Hospital; has consultant arrangements with AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, Inc, Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, Inc, International Meetings and Science, Scienomics, Scientific Therapeutics, and Cognimed, Inc, is an author for Up-to-Date; and is a textbook editor for Elsevier, Inc. The rest of the authors have declared that they have no conflicts of interest. |
© 2010
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 127 - N° 2
P. 550 - février 2011 Retour au numéro
Article précédent
- Forced expiratory flow between 25% and 75% of vital capacity may be a marker of bronchial impairment in allergic rhinitis
- Giorgio Ciprandi, Ignazio Cirillo
- Reply
- Giorgio Ciprandi, Ignazio Cirillo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?